Eli Lilly and Company stock climbed roughly 3.9% in pre-open trading after the closing session of the American Diabetes Association’s 86th Scientific Sessions in New Orleans devoted a symposium to Phase 3 data for Foundayo (orforglipron), the company’s oral GLP-1 therapy that does not require food or water restrictions.
The ACHIEVE program results presented at the symposium showed Foundayo reduced A1C by as much as 1.7%, compared with a 0.8% reduction with dapagliflozin, and were reported to be superior to oral semaglutide for type 2 diabetes. At the 52-week mark Foundayo delivered stronger A1C lowering and significantly greater relative weight loss versus oral semaglutide, according to the data disclosed.
The Foundayo presentation capped several days of positive trial news from Lilly at the ADA conference. Earlier in the meeting the company disclosed new pivotal Phase 3 results for retatrutide, a first-in-class triple hormone receptor agonist that targets GIP, GLP-1, and glucagon receptors. That program showed substantial weight loss and also reported meaningful improvements in knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes.
Additional subgroup analyses from the ATTAIN program were also released, indicating that Foundayo was linked to significant weight loss across menopausal stages, including reductions of more than 14% in women who were peri-menopausal or post-menopausal.
Beyond clinical data, Lilly announced corporate transactions that added to the positive tone. The company signed a licensing agreement related to an intestinal treatment and entered a collaboration and licensing deal with a unit of China’s Haisco Pharmaceutical Group. Separately, Lilly said its Phase 3 Libretto-432 trial of Retevmo met its primary endpoint.
Analyst commentary provided further support for the shares. Bank of America increased its price target on Eli Lilly to $1,251 from $1,133 while maintaining a Buy rating on the stock.
Today’s pre-market gain came despite a markedly weaker broader U.S. equity market, with the S&P 500 declining and the NASDAQ falling sharply. Lilly’s presentations at the ADA spanned the June 5-8 conference window in New Orleans, and the company is scheduled to appear at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, keeping institutional attention on the name heading into the coming week.
Competitor Novo Nordisk, whose Wegovy is a rival to Zepbound, was also present at the ADA. Analysts at William Blair noted that retatrutide occupies a "different drug category" given its high potency, positioning it distinct from Lilly’s existing obesity offerings.
The accumulation of company-specific catalysts - leading Phase 3 obesity data, a focused Foundayo symposium on the ADA conference’s final day, fresh licensing and collaboration agreements, and a constructive analyst price-target adjustment - was sufficient to propel LLY higher against a broadly risk-off market.
Lilly expects retatrutide to represent its next incretin approval and has stated it anticipates having "as many as five approved obesity medicines" by the end of the decade. That depth of pipeline candidates is a highlight for investors, supporting confidence in the stock even as macroeconomic pressures weigh on broader market indices.
Summary
Shares of Eli Lilly rose in pre-market trading after the ADA conference’s final-day symposium showcased strong Phase 3 data for Foundayo, complementing recent positive results for retatrutide and additional subgroup and corporate announcements. A Bank of America price-target increase and scheduled participation at a major healthcare conference kept investor focus on the company despite weakness in broader U.S. equities.
Key points
- Clinical: Foundayo lowered A1C up to 1.7% versus 0.8% with dapagliflozin and showed superior A1C reduction and greater relative weight loss than oral semaglutide at 52 weeks.
- Pipeline breadth: Retatrutide Phase 3 results demonstrated substantial weight loss plus improvements in knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes; Lilly projects retatrutide to be its next incretin approval and expects up to five approved obesity medicines by decade-end.
- Corporate and market: Lilly announced licensing and collaboration agreements, reported a Phase 3 Libretto-432 trial success for Retevmo, and received a Bank of America price target raise, all while broader U.S. indices were under pressure.
Risks and uncertainties
- Broader market volatility: The S&P 500 and NASDAQ experienced notable declines, a backdrop that can pressure stock performance even when company-specific news is positive, affecting equity and healthcare sector sentiment.
- Competitive landscape: Competitors, including Novo Nordisk, are active at the same conferences and markets for obesity and diabetes therapies, creating an environment where product positioning and perceived differentiation matter to investors and payors.
- Execution and regulatory pathways: While the company reported multiple positive trial results and deals, the path from Phase 3 data to approvals and commercial rollouts remains subject to regulatory review and execution risks that could influence future outcomes.